Top

Published in:

01-08-2013 | Original Article

Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia

Authors: Olaposi Yomade, Bärbel Spies-Weisshart, Anita Glaser, Ulf Schnetzke, Andreas Hochhaus, Sebastian Scholl

Published in: Annals of Hematology | Issue 8/2013

Abstract

We sought to investigate the relationship between polymorphisms of the NOD2 gene and infectious complications following intensive induction chemotherapy in patients with acute myeloid leukaemia (AML). We hypothesised that single nucleotide polymorphisms (SNPs) of the NOD2 gene are associated with a higher rate of infections during the phase of severe neutropenia. In 131 AML patients receiving induction therapy, the presence of the three most frequent polymorphisms of NOD2 (Arg702Trp, Gly908Arg, Leu1007fsinsC) was analysed. SNP analyses by means of genomic PCR incorporating fluorescence-labelled probes with characteristic melting curves were performed using the LightCycler platform. Our data suggest a significantly lower probability of mucositis or enteritis in AML patients lacking any of the three evaluated NOD2 polymorphisms. Furthermore, bloodstream cultures of AML patients carrying either a missense or a frameshift mutation of NOD2 were significantly more frequently tested positive concerning Streptococcus spp. In contrast, the presence of NOD2 polymorphisms had no impact on such important infectious complications as systemic inflammatory response syndrome or sepsis, the rate of central venous catheter infections or the incidence of pneumonia including fungal infections. Our data represent one of the first reports investigating the impact of polymorphisms of the innate immune system on infectious complications in patients with neutropenia following chemotherapy. A correlation between NOD2 polymorphisms and infectious events in AML patients is demonstrated.

Damon LE et al (1994) Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia. Leukemia 8(4):535–41PubMed

Gupta A et al (2010) Infections in acute myeloid leukemia: an analysis of 382 febrile episodes. Med Oncol 27(4):1037–45PubMedCrossRef

Syrjala H et al (2010) Blood stream infections during chemotherapy-induced neutropenia in adult patients with acute myeloid leukemia: treatment cycle matters. Eur J Clin Microbiol Infect Dis 29(10):1211–8PubMedCrossRef

Specchia G et al (2003) Pneumonia in acute leukemia patients during induction therapy: experience in a single institution. Leuk Lymphoma 44(1):97–101PubMedCrossRef

Brown KL et al (2007) Complexities of targeting innate immunity to treat infection. Trends Immunol 28(6):260–6PubMedCrossRef

Ito T et al (2012) Notch system in the linkage of innate and adaptive immunity. J Leukoc Biol 92(1):59–65PubMedCrossRef

Elphick DA, Mahida YR (2005) Paneth cells: their role in innate immunity and inflammatory disease. Gut 54(12):1802–9PubMedCrossRef

Selsted ME, Ouellette AJ (2005) Mammalian defensins in the antimicrobial immune response. Nat Immunol 6(6):551–7PubMedCrossRef

Gutierrez O et al (2002) Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. J Biol Chem 277(44):41701–5PubMedCrossRef

10.

Lala S et al (2003) Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterology 125(1):47–57PubMedCrossRef

11.

Girardin SE et al (2003) Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278(11):8869–72PubMedCrossRef

12.

Ogura Y et al (2001) Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 276(7):4812–8PubMedCrossRef

13.

Hugot JP et al (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411(6837):599–603PubMedCrossRef

14.

Ogura Y et al (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411(6837):603–6PubMedCrossRef

15.

Li J et al (2004) Regulation of IL-8 and IL-1beta expression in Crohn's disease associated NOD2/CARD15 mutations. Hum Mol Genet 13(16):1715–25PubMedCrossRef

16.

Netea MG et al (2005) NOD2 3020insC mutation and the pathogenesis of Crohn's disease: impaired IL-1beta production points to a loss-of-function phenotype. Neth J Med 63(8):305–8PubMed

17.

Kobayashi KS et al (2005) Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 307(5710):731–4PubMedCrossRef

18.

Uehara A et al (2007) Various human epithelial cells express functional Toll-like receptors, NOD1 and NOD2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol Immunol 44(12):3100–11PubMedCrossRef

19.

Wehkamp J et al (2004) NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 53(11):1658–64PubMedCrossRef

20.

Bevins CL, Stange EF, Wehkamp J (2009) Decreased Paneth cell defensin expression in ileal Crohn's disease is independent of inflammation, but linked to the NOD2 1007fs genotype. Gut 58(6):882–3, discussion 883–4PubMed

21.

Van der Graaf CA et al (2006) Toll-like receptor 4 Asp299Gly/Thr399Ile polymorphisms are a risk factor for Candida bloodstream infection. Eur Cytokine Netw 17(1):29–34PubMed

22.

Wurfel MM et al (2008) Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med 178(7):710–20PubMedCrossRef

23.

Brenmoehl J et al (2007) Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients. Intensive Care Med 33(9):1541–8PubMedCrossRef

24.

Klostergaard A et al (2010) Sepsis in acute myeloid leukaemia patients receiving high-dose chemotherapy: no impact of chitotriosidase and mannose-binding lectin polymorphisms. Eur J Haematol 85(1):58–64PubMed

25.

Choi EH et al (2005) Common polymorphisms in critical genes of innate immunity do not contribute to the risk for chronic disseminated candidiasis in adult leukemia patients. Med Mycol 43(4):349–53PubMedCrossRef

26.

Holler E et al (2004) Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 104(3):889–94PubMedCrossRef

27.

Elmaagacli AH et al (2006) Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation. Transplantation 81(2):247–54PubMedCrossRef

28.

Estey E, Dohner H (2006) Acute myeloid leukaemia. Lancet 368(9550):1894–907PubMedCrossRef

29.

Becker C et al (2004) High complete remission rate in patients with acute myeloid leukemia (AML) above the age of 60 years: A report of the AML97#38 Study of the East German Hematology and Oncology Study Group. ASH Annual Meeting Abstracts 104(11):880

30.

Basara N et al (2009) Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission. Leukemia 23(4):635–40PubMedCrossRef

31.

Ruegg C et al (2004) Detection of the Arg702Trp, Gly908Arg and Leu1007fsinsC polymorphisms of the NOD2/CARD15 gene by real-time PCR with melting curve analysis. Clin Chem Lab Med 42(5):494–8PubMedCrossRef

32.

Reinhart K et al. (2010) Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinare Vereinigung fur Intensiv- und Notfallmedizin (DIVI)). Ger Med Sci 8: p Doc14

33.

De Pauw B et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12):1813–21PubMedCrossRef

34.

Lecat A, Piette J, Legrand-Poels S (2010) The protein Nod2: an innate receptor more complex than previously assumed. Biochem Pharmacol 80(12):2021–31PubMedCrossRef

35.

Kaser A, Niederreiter L, Blumberg RS (2011) Genetically determined epithelial dysfunction and its consequences for microflora-host interactions. Cell Mol Life Sci 68(22):3643–9PubMedCrossRef

36.

Cuthbert AP et al (2002) The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 122(4):867–74PubMedCrossRef

37.

Camera A et al (2003) Intestinal toxicity during induction chemotherapy with cytarabine-based regimens in adult acute myeloid leukemia. Hematol J 4(5):346–50PubMedCrossRef

38.

Hogan WJ et al (2002) Neutropenic colitis after treatment of acute myelogenous leukemia with idarubicin and cytosine arabinoside. Mayo Clin Proc 77(8):760–2PubMedCrossRef

39.

Opitz B et al (2004) Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J Biol Chem 279(35):36426–32PubMedCrossRef

40.

Koppe U, Suttorp N, Opitz B (2012) Recognition of Streptococcus pneumoniae by the innate immune system. Cell Microbiol 14(4):460–6PubMedCrossRef

41.

Henckaerts L et al (2009) Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit. Crit Care Med 37(1):192–201, e1-3PubMedCrossRef

42.

Wong M et al (2012) Mannose-binding lectin 2 polymorphisms do not influence frequency or type of infection in adults with chemotherapy induced neutropaenia. PLoS One 7(2):e30819PubMedCrossRef

Title: Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia
Authors: Olaposi Yomade
Bärbel Spies-Weisshart
Anita Glaser
Ulf Schnetzke
Andreas Hochhaus
Sebastian Scholl
Publication date: 01-08-2013
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 8/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-013-1734-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2013

Bortezomib induced a phrenic palsy in a multiple myeloma patient

Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma

Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome

Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations

Polymorphisms of the IL-23R gene are associated with primary immune thrombocytopenia but not with the clinical outcome of pulsed high-dose dexamethasone therapy

Profound thrombocytopenia in patient with ITP treated with chemotherapy for breast cancer and subsequent remission after romiplostim

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials